Suvorexant

Suvorexant
Systematic (IUPAC) name
	[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
Clinical data
Pregnancy cat.	?
Legal status	Investigational
Identifiers
CAS number	1030377-33-3
ATC code	None
PubChem	CID 24965990
ChemSpider	24662178
Chemical data
Formula	C23H23ClN6O2
Mol. mass	450.920 g/mol (free base)
	SMILES n5ccnn5-c3ccc(C)cc3C(=O)N2CCN(CCC2C)c(nc1c4)oc1ccc4Cl;
	InChI InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1; Key:JYTNQNCOQXFQPK-MRXNPFEDSA-N ;
(what is this?) (verify);

Suvorexant (MK-4305) is a dual orexin receptor antagonist in development by Merck & Co.^[1]^[2]^[3] Suvorexant works by turning off wakefulness rather than by inducing sleep.^[4] It is not currently approved for commercial use, but it has completed three Phase III trials.^[5] It is one of two such compounds currently in development, the other being GlaxoSmithKline's SB-649,868.^{[citation needed]}

[edit] References

^ Cox, Christopher D.; Breslin, Michael J.; Whitman, David B.; Schreier, John D.; McGaughey, Georgia B.; Bogusky, Michael J.; Roecker, Anthony J.; Mercer, Swati P. et al. (2010). "Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia". Journal of Medicinal Chemistry 53 (14): 5320–32. doi:10.1021/jm100541c. PMID 20565075. |displayauthors= suggested (help) edit
^ Baxter, Carl A.; Cleator, Ed; Brands, Karel M. J.; Edwards, John S.; Reamer, Robert A.; Sheen, Faye J.; Stewart, Gavin W.; Strotman, Neil A. et al. (2011). "The First Large-Scale Synthesis of MK-4305: A Dual Orexin Receptor Antagonist for the Treatment of Sleep Disorder". Organic Process Research & Development 15 (2): 367–75. doi:10.1021/op1002853. |displayauthors= suggested (help) edit
^ Winrow, Christopher J.; Gotter, Anthony L.; Cox, Christopher D.; Doran, Scott M.; Tannenbaum, Pamela L.; Breslin, Michael J.; Garson, Susan L.; Fox, Steven V. et al. (2011). "Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist". Journal of Neurogenetics 25 (1–2): 52–61. doi:10.3109/01677063.2011.566953. PMID 21473737. |displayauthors= suggested (help) edit
^ Kahn, Howie (June 1, 2012). "Sleep Better". In Koerth-Baker, Maggie. 32 Innovations That Will Change Your Tomorrow. New York Times. Retrieved November 29, 2012.
^ Three completed trials:

This sedative-related article is a stub. You can help Wikipedia by expanding it.

Actelion's research team is targeting the G-Protein coupled receptors, OX1 and OX2, which mediate the actions of orexins.